Combined EGFR and VEGFR versus single EGFR signaling pathways inhibition therapy for NSCLC: a systematic review and meta-analysis.
<h4>Background</h4>Lung cancer is a heterogeneous disease with multiple signaling pathways influencing tumor cell survival and proliferation, and it is likely that blocking only one of these pathways allows others to act as salvage or escape mechanisms for cancer cells. Whether combined...
Saved in:
| Main Authors: | Xinji Zhang, Yesheng Li, Hui Li, Yingyi Qin, Chong Bai, Feng Xu, Tianyi Zhu, Jinfang Xu, Mengjie Wu, Chaoxiang Wang, Lixin Wei, Jia He |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2012-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0040178&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Sd-021, derivatives of decursin, inhibits tumorigenesis in NSCLC by inhibiting the EGFR/STAT3 signaling pathway
by: Hyun-Ha Hwang, et al.
Published: (2025-07-01) -
Comparison of first-generation EGFR-TKIs combined with low-dose bevacizumab versus osimertinib in untreated advanced EGFR-mutated NSCLC
by: Yingqi Xu, et al.
Published: (2025-12-01) -
Clinical characteristics of EGFR-ctDNA shedders in EGFR-mutant NSCLC patients
by: Martina Ruglioni, et al.
Published: (2025-02-01) -
Combination of betulinic acid and EGFR-TKIs exerts synergistic anti-tumor effects against wild-type EGFR NSCLC by inducing autophagy-related cell death via EGFR signaling pathway
by: Han Wang, et al.
Published: (2024-05-01) -
EGFR-Targeted Therapeutics: Focus on SCCHN and NSCLC
by: Martin Sattler, et al.
Published: (2008-01-01)